| |
|
|
|
|
|
|
|||
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4557-4563. Prepublished online as a Blood First Edition Paper on January 23, 2007; DOI 10.1182/blood-2006-05-021139.
TRANSPLANTATION A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease1 Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle; 2 DOR BioPharma Inc, Miami, FL; 3 Vanderbilt University School of Medicine, Nashville, TN; 4 Hackensack University Medical Center, NJ; 5 City of Hope National Medical Center, Duarte, CA; 6 Rocky Mountain Blood & Marrow Transplant Program, Denver, CO; 7 Baylor University School of Medicine, Dallas, TX; 8 Oncology & Hematology Associates, Kansas City, MO We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea. Patients were randomized to prednisone for 10 days and either oral BDP 8 mg/d (n = 62) or placebo (n = 67) tablets for 50 days. At study day 10, prednisone was rapidly tapered while continuing study drug. On an intent-to-treat basis, the risk of GVHD-treatment failure was reduced for the BDP group at study day 50 (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.35-1.13) and at 30 days follow-up (HR 0.55, 95% CI 0.32-0.93). Among patients eligible for prednisone taper at study day 10, the risk of GVHD-treatment failure was significantly reduced at both study days 50 and 80 (HR 0.39 and 0.38, respectively). By day 200 after transplantation, 5 patients randomized to BDP had died compared with 16 deaths on placebo, a 67% reduction in the hazard of mortality (HR 0.33, P = .03). In 47 recipients of unrelated and HLA-mismatched stem cells, mortality at transplantation day 200 was reduced by 91% in the BDP group compared with placebo (HR 0.09, P = .02). The survival benefit was durable to 1 year after randomization. Oral BDP prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving BDP.
Find additional patient-related information at:
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||